However, we need to keep in mind that the effect of PCSK9 inhibitors also depends on their residual LDLR activity, and, thus, its effectiveness is quite limited in cases of homozygous FH patients, especially those whose residual LDLR activity is null [1]. Here, PCSK9 is linked to familial hyperaldosteronism.